Zai Lab Limited
NASDAQ:ZLABBiotechnology
+$0.61 today
- Market cap
- $2.49B
- Beta
- 0.78
- P/E (TTM)
- -11.4
- EPS (TTM)
- -$0.16
Volume 1.04M
Average 0.87M
ZLAB Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Zai Lab LimitedNASDAQ: ZLAB
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $61.77M rose 22.0% year over year, ahead of the +3.2% change in trailing-twelve-month research & development. Sequentially, it fell 5.8% from the prior quarter. Over 3 fiscal years it compounded at -8.3% a year.
Context
- Research & development amounted to 48.0% of revenue in FY2025, down 10.8 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +22.0% holds above the trailing-twelve-month pace of +3.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 220.9M USD
- Year-over-year change
- -5.8%
- 4-year CAGR
- -21.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 220.9M | -5.8% |
| FY2024 | 2024-12-31 | 234.5M | -11.8% |
| FY2023 | 2023-12-31 | 265.87M | -7.2% |
| FY2022 | 2022-12-31 | 286.41M | -50.0% |
| FY2021 | 2021-12-31 | 573.31M | — |
Research & Development vs competitors
How ZLAB compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +3.2% is the 2nd highest of 3, against a peer median of -5.4%.
- Research & development amounts to 52.7% of revenue for ZLAB, versus a peer median of 194.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | FY2025 | CN¥1.08B CNY | +14.4% | +13.4% | 194.0% |
| LTM Jun 2026 | $236.92M USD | +3.2% | -8.3% | 52.7% | |
| LTM Jun 2025 | $190.1M USD | -25.1% | -15.0% | 31.6% | |
| LTM Jun 2024 | $56.93M USD | — | -15.5% | 877.1% | |
| Peer median (excluding ZLAB) | — | -5.4% | -15.0% | 194.0% | |
Competitors are the stored peer set for ZLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 144.31M | 215.04M | 266.72M | 398.99M | 460.16M |
| Cost of Revenue | 52.24M | 74.02M | 95.82M | 147.86M | 191.08M |
| Gross Profit | 92.07M | 141.02M | 170.9M | 251.13M | 269.08M |
| Gross Margin | 63.8% | 65.6% | 64.1% | 62.9% | 58.5% |
| Research & Development | 573.31M | 286.41M | 265.87M | 234.5M | 220.9M |
| Selling, General & Admin | 218.83M | 258.97M | 281.61M | 298.74M | 277.61M |
| Operating Expenses | 792.14M | 545.38M | 537.48M | 533.25M | 492.65M |
| Depreciation & Amortization | 6.49M | 8.23M | 9.03M | 11.86M | 15.01M |
| EBITDA | (689.46M) | (434.84M) | (365.11M) | (242.99M) | (158.25M) |
| EBITDA Margin | -477.8% | -202.2% | -136.9% | -60.9% | -34.4% |
| Operating Income | (700.06M) | (404.36M) | (366.57M) | (282.12M) | (223.57M) |
| Operating Margin | -485.1% | -188.0% | -137.4% | -70.7% | -48.6% |
| Interest Income | 2.19M | 14.58M | 39.8M | 37.11M | 33.05M |
| Interest Expense | 0 | 0 | 0 | 2.25M | 5.21M |
| Other Income / Expenses | (3.35M) | (38.93M) | 31.95M | 25.01M | 45.11M |
| Income Before Tax | (703.41M) | (443.29M) | (334.62M) | (257.1M) | (178.46M) |
| Pre-Tax Margin | -487.4% | -206.1% | -125.5% | -64.4% | -38.8% |
| Income Tax Expense | 1.06M | 0 | 0 | 0 | (2.93M) |
| Net Income | (704.47M) | (443.29M) | (334.62M) | (257.1M) | (175.54M) |
| Net Margin | -488.2% | -206.1% | -125.5% | -64.4% | -38.1% |
| EPS (Basic) | (75.80) | (46.30) | (34.60) | (2.60) | (1.60) |
| EPS (Diluted) | (75.80) | (46.30) | (34.60) | (2.60) | (1.60) |
| Weighted Avg Shares | 9.3M | 9.58M | 9.66M | 98.95M | 109.53M |
| Weighted Avg Shares (Diluted) | 9.3M | 9.58M | 9.66M | 98.95M | 109.53M |
Zai Lab Limited
NASDAQ:ZLAB
Intrinsic Alpha fair value
Locked
Current Price
$22.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.